Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FourLight-3: PF-07220060 plus letrozole vs CDK4/6 inhibitor plus letrozole in HR-positive, HER2-negative advanced/metastatic breast cancer
2024-512925-95-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, open-label trial of atirmociclib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival by blinded independent central review. Planned start Apr 2025; status: authorised.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-512925-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512925-95-00.